Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Chimeric Therapeutics has reported significant progress in its CHM CDH17 Phase 1/2 clinical trial, advancing to dose level 2 with promising safety and efficacy results. The trial has shown manageable safety profiles and encouraging disease control in patients, with notable tumor size reductions in colorectal and neuroendocrine cancers. Additionally, the company has strengthened its leadership by appointing Professor Miles Prince as a Non-Executive Director and has signed a local manufacturing agreement with the New South Wales Government, potentially enhancing its operational capabilities.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is a leading Australian cell therapy company focused on developing innovative treatments in the biotechnology sector. The company specializes in cell therapy products, particularly CAR-T cell therapies, aimed at treating various cancers.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.